Patent · US Active

Method of treating diabetes type 2 by administering ultrarapid acting insulin

US10857207B2 · kind B2 · utility

0Cited by
0References
5Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 2, 2018
Grant dateDec 8, 2020
Priority date
Expiry dateJun 7, 2038

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P43/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.